LEAVITT PARTNERS, LLC for PEDIATRIC INCLUSION ALLIANCE
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
As part of the upcoming reauthorization of FDAs medical product user fee programs, direct FDA to prioritize pediatric inclusion efforts byestablishing clearer, more consistent policies and practices for including children in clinical trials as early as scientifically and ethically appropriate.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA SINGLETON | Deputy Assistant Secretary-HHS; Policy Advisor- Senate; LegislativeAssistant- Senate; Policy Fellow- Senate |
Medical/Disease Research/Clinical Labs MED
As part of the upcoming reauthorization of FDAs medical product user fee programs, direct FDA to prioritize pediatric inclusion efforts by establishing clearer, more consistent policies and practices for including children in clinical trials as early as scientifically and ethically appropriate.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA SINGLETON | Deputy Assistant Secretary-HHS; Policy Advisor- Senate; LegislativeAssistant- Senate; Policy Fellow- Senate |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.